Please wait a minute...
文章检索
预防医学  2019, Vol. 31 Issue (4): 381-384,389    DOI: 10.19485/j.cnki.issn2096-5087.2019.04.014
  疾病控制 本期目录 | 过刊浏览 | 高级检索 |
姜黄素对溃疡性结肠炎小鼠结肠组织病变及细胞因子表达水平的影响
徐磊, 沈雁, 钟继红, 王章流, 郑华君, 许国富
浙江中医药大学附属第二医院,浙江 杭州 310005
全文: PDF(518 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨姜黄素对溃疡性结肠炎(UC)小鼠结肠病变及促炎细胞因子、抗炎细胞因子表达水平的影响,为姜黄素防治UC提供依据。方法 将50只SPF级BALB/c小鼠随机分为空白对照组、模型对照组、柳氮磺胺吡啶(SASP)对照组、姜黄素低剂量组和姜黄素高剂量组,每组10只。采用右旋葡聚糖硫酸钠(DSS)诱导法建立UC小鼠模型。观察小鼠临床症状,末次给药后处死小鼠,进行结肠大体形态损伤指数(CMDI)评分,光镜下观察结肠组织的病理学变化并评估组织损伤指数(TDI),采用酶联免疫吸附试验检测小鼠结肠组织中促炎细胞因子IL-6、IL-17和抗炎细胞因子IL-10、TGF-β的表达水平。结果 姜黄素低剂量组和高剂量组的CMDI评分分别为(2.32±1.12)和(2.17±1.10)分,均低于模型对照组的(3.86±1.47)分(P<0.01);姜黄素低剂量组和高剂量组的TDI评分分别为(6.34±1.01)和(6.01±1.02)分,均低于模型对照组的(8.91±0.89)分(P<0.01)。姜黄素低剂量组和高剂量组的IL-6含量分别为(78.74±13.29)和(72.28±12.33)pg/mL,IL-17含量分别为(30.23±0.89)和(29.72±1.26)pg/mL,均低于模型对照组的(108.64±17.24)和(36.11±1.36)pg/mL(P<0.01);姜黄素低剂量组和高剂量组的IL-10含量分别为(136.66±16.49)和(146.26±17.59)pg/mL,TGF-β含量分别为(274.21±27.46)和(286.32±28.65)pg/mL,均高于模型对照组的(33.96±6.68)和(249.96±42.98)pg/mL(P<0.01)。结论 姜黄素可以改善UC小鼠的临床症状,减轻结肠组织损伤,上调IL-10、TGF-β表达水平并抑制IL-6、IL-17表达水平,纠正促炎-抑炎细胞因子失衡状态。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
徐磊
沈雁
钟继红
王章流
郑华君
许国富
关键词 姜黄素溃疡性结肠炎细胞因子    
收稿日期: 2018-10-16           出版日期: 2019-04-02
中图分类号:  R285.5  
  R574.62  
基金资助:浙江省中医药科技计划项目(2018ZA056); 浙江中医药大学校级科研基金重点项目(2015ZZ07)
通信作者: 徐磊,E-mail:supershilling@sina.cn   
作者简介: 徐磊,硕士,主治中医师,主要从事消化内科临床工作
引用本文:   
徐磊, 沈雁, 钟继红, 王章流, 郑华君, 许国富. 姜黄素对溃疡性结肠炎小鼠结肠组织病变及细胞因子表达水平的影响[J]. 预防医学, 2019, 31(4): 381-384,389.
链接本文:  
http://www.zjyfyxzz.com/CN/Y2019/V31/I4/381
[1] ABRALLAM C,CHO J.Inflammatory bowel disease[J]. N Engl J Med,2009,361(21):2066-2078.
[2] AHUJA V,TANDON R K.Inflammatory bowel disease in the Asia-Pacific area:a comparison with developed countries and regional differences[J]. Dig Dis,2010,11(3):134-147.
[3] SCHIRBEL A,FIOCCHI C.Inflammatory bowel disease:established and evolving considerations on its etiopathogenesis and therapy[J]. Dig Dis,2010,11(5):266-276.
[4] ENGEL M A,NEURATH M F.New pathophysiological insights and modern treatment of IBD[J]. Gastroenterol,2010,45(6):571-583.
[5] ALLOCCA M,JOVANI M,FIORINO G,et al.Anti-IL-6 treatment for inflammatory bowel diseases:next cytokine,next target[J]. Curr Drug Targets,2013,14(12):1508-1521.
[6] GOEL A,KUNNUMAKKARA A B,AGGARWAL B B.Curcumin as "curecumin":from kitchen to clinic[J]. Biochem Pharmacol,2008,75(4):787-809.
[7] SIKORA E,SCAPAGNINI G,BARBAGALLO M.Curcumin,inflammation,ageing and age-related diseases[J]. Immunity & Ageing,2010,7(1):1.
[8] REUTER S,EIFES S,DICATO M,et al.Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells[J]. Biochemical Pharmacology,2008,76(11):1340-1351.
[9] LIU L,LIU Y L,LIU G X,et al.Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway[J]. Int Immunopharmacol,2013,17(2):314-320.
[10] ARAFA H M,HEMEIDA R A,EL-BAHRAWY A I,et al. Prophylactic role of curcumin in dextran sulfate sodium(DSS)-induced ulcerative colitis murine model[J]. Food Chem Toxicol,2009,47(6):1311-1317.
[11] EPSTEIN J,DOCENA G,MACDONALD T T,et al.Curcumin suppresses p38 mitogen-activated protein kinase activation,reduces IL-1β and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease[J]. Br J Nutr,2010,103(6):824-832.
[12] LUBBAD A,ORIOWO M A,KHAN I.Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis[J]. Molecular & Cellular Biochemistry,2009,322(1- 2):127-135.
[13] MORRIS G P,BECK P L,HERRIDGE M S,et al.Hapten-induced model of chronic inflammation and ulceration in the rat colon[J]. Gastroenterology,1989,96(3):795-803.
[14] PAIOTTI A P,RIBEIRO D A,SILVA R M,et al.Effect of CO4X-2 inhibitor lumiracoxib and the TNF-α antagonist etanercept on TNPS-induced colitis in Wistar rats[J]. Mol Histol,2012,43(3):307-317.
[15] DIELEMAN L A,PALMEN M J,AKOL H,et al.Chronic experimental colitis induced by dextran sulphate sodium(DSS)is characterized by Th1 and Th2 cytokines[J]. Clin Exp Immunol,1998, 114(3):385-391.
[16] NDUJAR I A,RIOS J L,GINER R M,et al.Beneficial effect of shikonin on experimental colitis induced by dextran sulfate sodium in Balb/c mice[J]. Evid Based Complement Alternat Med,2012(38):271606.
[17] WINE E,MACK D R,HYAMS J,et al.Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis[J]. J Crohns Colitis,2013,7(1):916-922.
[18] VAN K C,BELAICHE J,LOUIS E.Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission[J]. Int J Colorectal Dis,2000,15(4):206-210.
[19] FUJINO S,ANDOH A,BAMBA S,et al.Increased expresion of interleukin17 in inflammatory bowel disease[J]. Gut,2003,52(1):65-70.
[20] ATREYA R,ATREYA I,NEURATH M F,et al.Novel signal transduction pathways:analysis of Stat-3 and Rac-1 signaling in infammatory bowel disease[J]. Annals of the New York Academy of Sciences, 2010,1072(1):98-113.
[21] EASTAFF-LEUNG N,MABARRACK N,BARBOUR A,et al.FOXP3+regulatory T cells,Th17 effector cells,and cytokine environment in inflammatory bowel disease[J]. J Clin Immunol,2010,30(1):80-89.
[22] SANSONE P,BROMBERG J.Targeting the interleukin-6/Jak/Stat pathway in human malignancie[J]. J Clin Oncol,2012,30(9):1005.
[23] ZHOU L,LITTAN D R.Transcriptional regulatory networks in Th17 cell differentiation[J]. Curr Opin Immtmol,2009,21(2):146-152.
[24] MUCIDA D,PARK Y,KIM G,et al.Reciprocal Th17 and regulatory T cell differentiation mediated by retinoic acid[J]. Science,2007,317(5835):256-260.
[1] 迪娜·木合亚提, 吕梅霞, 木海热姆·杰力力, 韩加. 维吾尔族居民脂肪细胞相关因子与超重、肥胖的关联分析[J]. 预防医学, 2021, 33(7): 704-706.
[2] 考庆君, 吴彦, 王兵, 张国忠, 孙昼, 赵俊. 手足口病儿童血清细胞因子分析[J]. 预防医学, 2021, 33(5): 497-499.
[3] 沈雁, 李思, 钟继红, 徐磊, 王章流, 郑华君. 小檗碱对溃疡性结肠炎小鼠结肠组织紧密连接蛋白claudin-1表达的影响[J]. 预防医学, 2017, 29(11): 1098-1103.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed